Vertex, CRISPR’s Gene-Editing Therapy Casgevy Wins Early FDA Nod

he FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology.